fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA and Novo Nordisk Warn

Why claims data alone cant explain real-world GLP-1 outcomes As adoption accelerates, pharmaceutical companies are racing to innovate through new formulations, delivery options, and combination approaches that improve tolerability and long-term outcomes

Moreover, we found that GLP-1(2836) failed to protect sAC / caSMCs from oxidative stress injury, as evidenced by nonsignificant decreases in LDH release versus the scrambled control (0.74 0.03 vs

Verrotti A, et al

Conclusion: Streamlining GLP-1 Access and Adherence As the national shortage of GLP-1 medications begins to ease, pharmacies are improving access to these life-changing treatments

Not intended for medical, therapeutic, or diagnostic purposes.

Water activity The water activity of the vegan athlete protein powder samples was determined using a Testo-AG 400 water activity analyzer, which offers a precision level of 0.001